Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-03T00:30:50.056Z Has data issue: false hasContentIssue false

10 - Antivascular therapy in gynaecological cancers

from SECTION 3 - IMAGING AND THERAPY: STATE OF THE ART

Published online by Cambridge University Press:  05 February 2014

Leena Mukherjee
Affiliation:
Mount Vernon Cancer Centre
Gordon Rustin
Affiliation:
Mount Vernon Cancer Centre
Sean Kehoe
Affiliation:
John Radcliffe Hospital, Oxford
Richard J. Edmondson
Affiliation:
Queen Elizabeth Hospital, Gateshead
Martin Gore
Affiliation:
Institute of Cancer Research, London
Iain A. McNeish
Affiliation:
Barts and The London School of Medicine, London
Get access

Summary

The great majority of women with advanced ovarian cancer will relapse and die from their disease. There is therefore a great need for new agents that can extend remission and prolong survival. One approach is to introduce agents that target the vasculature that maintains a tumour's ability to survive and grow. These can be divided into agents that act against established blood vessels (vascular disrupting agents or VDAs) or inhibit the formation of new blood vessels (anti-angiogenic drugs). Angiogenesis inhibitors are considered to be cytostatic in nature, in contrast to VDAs, which are thought to be cytotoxic, but there is considerable overlap between the two groups, with agents classified according to their primary site of action (Box 10.1).

Angiogenesis is under dynamic regulation by stimulatory pro-angiogenic factors released by tumour and host cells, such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), interleukin 8 (IL-8), matrix metalloproteinases (MMPs) and inhibitory anti-angiogenic factors (tumour necrosis factor [TNF], 5-HT, angiostatin, endostatin). Diffusion of nutrients and oxygen from nearby capillaries beyond a tumour size of 2 mm is insufficient to sustain cell function. An imbalance of pro- and anti-angiogenic factors stimulates an angiogenic switch so that the tumour develops an angiogenic phenotype to grow and metastasise. Several process are thereafter involved, such as endothelial cell proliferation, proteolytic degradation of the extracellular matrix and migration of endothelial cells, leading to the formation of a functioning vessel with a lumen.

Type
Chapter
Information
Gynaecological Cancers
Biology and Therapeutics
, pp. 121 - 138
Publisher: Cambridge University Press
Print publication year: 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×